The HIV+Hepatitis Policy Institute strongly supports Michigan House Bill 43534, which would require health insurers to accept and count payments made on behalf of patients towards deductibles and out-of-pocket maximums and ask that you conduct a hearing on the bill as soon as possible.
The HIV+Hepatitis Policy Institute strongly support Assembly Bill 184, which would require health insurers and health care service contractors to accept and count payments made on behalf of patients towards deductibles and out-of-pocket maximums.
We strongly support Senate Bill 94, which would require health insurers to accept and count payments made on behalf of patients for prescription drugs towards their deductible and out-of-pocket maximum. This bill is scheduled to be voted on in the Senate on Monday, May 10th. We urge you to support this critical bill for patients.
The HIV+Hepatitis Policy Institute strongly supports The PBM Accountability Study Act (HR 1829), which would require the Government Accountability Office to provide a comprehensive report to Congress on the ways in which PBMs influence the pricing of pharmaceuticals, impede competition, use rebates and also provide recommendations on ways to lower prescription drug costs.
Letter to Secretary Becerra about Policies & Solutions to Improve Prescription Drug Affordability for Patients
We, the undersigned 124 organizations, on behalf of millions of patients and American consumers who live with complex conditions such as HIV, autoimmune diseases, cancer, diabetes, lupus, multiple sclerosis, and hepatitis, write to congratulate you on becoming Secretary and express our deep commitment and interest in working with you, the Department of Health and Human Services (HHS), and the Biden administration to implement policies and measures that improve prescription drug affordability and access for the American people.